+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global T-Cell Therapy Market by Modality (Commercialized, Research), Therapy Type (CAR T-cell Therapy, T Cell Receptor-Based, Tumor Infiltrating Lymphocytes-Based), Indication - Forecast 2024-2030- Product Image
Global T-Cell Therapy Market by Modality (Commercialized, Research), Therapy Type (CAR T-cell Therapy, T Cell Receptor-Based, Tumor Infiltrating Lymphocytes-Based), Indication - Forecast 2024-2030- Product Image
Sale

Global T-Cell Therapy Market by Modality (Commercialized, Research), Therapy Type (CAR T-cell Therapy, T Cell Receptor-Based, Tumor Infiltrating Lymphocytes-Based), Indication - Forecast 2024-2030

  • PDF Icon

    Report

  • 185 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5470745
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The T-Cell Therapy Market size was estimated at USD 8.13 billion in 2023, USD 9.85 billion in 2024, and is expected to grow at a CAGR of 21.23% to reach USD 31.30 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the T-Cell Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the T-Cell Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the T-Cell Therapy Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adaptimmune Therapeutics PLC, Amgen Inc., Bluebird Bio, Inc., Bristol Myers Squibb, DiaCarta, Inc., Fate Therapeutics Inc., Gilead Sciences, Inc., Merck KGaA, Novartis AG, Pfizer Inc., Poseida Therapeutics Inc., Sorrento Therapeutics, Inc., Takara Bio Inc., and Tessa Therapeutics Pte. Ltd.

Market Segmentation & Coverage

This research report categorizes the T-Cell Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Modality
    • Commercialized
    • Research
  • Therapy Type
    • CAR T-cell Therapy
    • T Cell Receptor-Based
    • Tumor Infiltrating Lymphocytes-Based
  • Indication
    • Hematologic Malignancies
      • Leukemia
      • Lymphoma
      • Myeloma
    • Solid Tumors
      • Brain & Central Nervous System
      • Liver Cancer
      • Melanoma
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the T-Cell Therapy Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the T-Cell Therapy Market?
  3. What are the technology trends and regulatory frameworks in the T-Cell Therapy Market?
  4. What is the market share of the leading vendors in the T-Cell Therapy Market?
  5. Which modes and strategic moves are suitable for entering the T-Cell Therapy Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. T-Cell Therapy Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing approvals along with expanding manufacturing capabilities
5.1.1.2. Alarming rate of increase in prevalence of cancers
5.1.1.3. Availability of adequate reimbursements with government awareness
5.1.2. Restraints
5.1.2.1. Limitations of efficacy of CAR T-cell immunotherapy and inadequate homing of CAR T-cells to tumor deposits
5.1.3. Opportunities
5.1.3.1. Exponential R&D funding for immuno-oncology sector
5.1.3.2. Expanding adoption of gene and cell therapy
5.1.4. Challenges
5.1.4.1. Safety issues and possible side-effects
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. T-Cell Therapy Market, by Modality
6.1. Introduction
6.2. Commercialized
6.3. Research
7. T-Cell Therapy Market, by Therapy Type
7.1. Introduction
7.2. CAR T-cell Therapy
7.3. T Cell Receptor-Based
7.4. Tumor Infiltrating Lymphocytes-Based
8. T-Cell Therapy Market, by Indication
8.1. Introduction
8.2. Hematologic Malignancies
8.3.1. Leukemia
8.3.2. Lymphoma
8.3.3. Myeloma
8.3. Solid Tumors
8.4.1. Brain & Central Nervous System
8.4.2. Liver Cancer
8.4.3. Melanoma
9. Americas T-Cell Therapy Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific T-Cell Therapy Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa T-Cell Therapy Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. AbbVie Inc.
13.1.2. Adaptimmune Therapeutics PLC
13.1.3. Amgen Inc.
13.1.4. Bluebird Bio, Inc.
13.1.5. Bristol Myers Squibb
13.1.6. DiaCarta, Inc.
13.1.7. Fate Therapeutics Inc.
13.1.8. Gilead Sciences, Inc.
13.1.9. Merck KGaA
13.1.10. Novartis AG
13.1.11. Pfizer Inc.
13.1.12. Poseida Therapeutics Inc.
13.1.13. Sorrento Therapeutics, Inc.
13.1.14. Takara Bio Inc.
13.1.15. Tessa Therapeutics Pte. Ltd.
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. T-CELL THERAPY MARKET RESEARCH PROCESS
FIGURE 2. T-CELL THERAPY MARKET SIZE, 2023 VS 2030
FIGURE 3. T-CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. T-CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. T-CELL THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. T-CELL THERAPY MARKET DYNAMICS
FIGURE 7. T-CELL THERAPY MARKET SIZE, BY MODALITY, 2023 VS 2030 (%)
FIGURE 8. T-CELL THERAPY MARKET SIZE, BY MODALITY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
FIGURE 10. T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. T-CELL THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 12. T-CELL THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES T-CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES T-CELL THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. T-CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. T-CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. T-CELL THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. T-CELL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL T-CELL THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 6. T-CELL THERAPY MARKET SIZE, BY COMMERCIALIZED, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. T-CELL THERAPY MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 9. T-CELL THERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. T-CELL THERAPY MARKET SIZE, BY T CELL RECEPTOR-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. T-CELL THERAPY MARKET SIZE, BY TUMOR INFILTRATING LYMPHOCYTES-BASED, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 13. T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 15. T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. T-CELL THERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. T-CELL THERAPY MARKET SIZE, BY MYELOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 20. T-CELL THERAPY MARKET SIZE, BY BRAIN & CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. T-CELL THERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. T-CELL THERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 29. ARGENTINA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 35. BRAZIL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 39. CANADA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 40. CANADA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 41. CANADA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 42. CANADA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 43. CANADA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 44. MEXICO T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 45. MEXICO T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 46. MEXICO T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 47. MEXICO T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 48. MEXICO T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES T-CELL THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 55. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 56. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 57. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 58. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 59. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 60. ASIA-PACIFIC T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 61. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 62. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 63. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 64. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 65. AUSTRALIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 66. CHINA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 67. CHINA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 68. CHINA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 69. CHINA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 70. CHINA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 71. INDIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 72. INDIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 73. INDIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 74. INDIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 75. INDIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 76. INDONESIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 77. INDONESIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 78. INDONESIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 79. INDONESIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 80. INDONESIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 81. JAPAN T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 82. JAPAN T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 83. JAPAN T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 84. JAPAN T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 85. JAPAN T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 86. MALAYSIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 87. MALAYSIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 88. MALAYSIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 89. MALAYSIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 90. MALAYSIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 91. PHILIPPINES T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 92. PHILIPPINES T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 93. PHILIPPINES T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 94. PHILIPPINES T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 95. PHILIPPINES T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 96. SINGAPORE T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 97. SINGAPORE T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 98. SINGAPORE T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 99. SINGAPORE T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 100. SINGAPORE T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 101. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 102. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 103. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 104. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 105. SOUTH KOREA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 106. TAIWAN T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 107. TAIWAN T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 108. TAIWAN T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 109. TAIWAN T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 110. TAIWAN T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 111. THAILAND T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 112. THAILAND T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 113. THAILAND T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 114. THAILAND T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 115. THAILAND T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 116. VIETNAM T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 117. VIETNAM T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 118. VIETNAM T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 119. VIETNAM T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 120. VIETNAM T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 127. DENMARK T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 128. DENMARK T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 129. DENMARK T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 130. DENMARK T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 131. DENMARK T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 132. EGYPT T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 133. EGYPT T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 134. EGYPT T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 135. EGYPT T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 136. EGYPT T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 137. FINLAND T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 138. FINLAND T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 139. FINLAND T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 140. FINLAND T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 141. FINLAND T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 142. FRANCE T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 143. FRANCE T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 144. FRANCE T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 145. FRANCE T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 146. FRANCE T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 147. GERMANY T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 148. GERMANY T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 149. GERMANY T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 150. GERMANY T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 151. GERMANY T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 152. ISRAEL T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 153. ISRAEL T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 154. ISRAEL T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 155. ISRAEL T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 156. ISRAEL T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 157. ITALY T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 158. ITALY T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 159. ITALY T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 160. ITALY T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 161. ITALY T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 162. NETHERLANDS T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 163. NETHERLANDS T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 164. NETHERLANDS T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 165. NETHERLANDS T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 166. NETHERLANDS T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 167. NIGERIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 168. NIGERIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 169. NIGERIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 170. NIGERIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 171. NIGERIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 172. NORWAY T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 173. NORWAY T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 174. NORWAY T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 175. NORWAY T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 176. NORWAY T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 177. POLAND T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 178. POLAND T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 179. POLAND T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 180. POLAND T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 181. POLAND T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 182. QATAR T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 183. QATAR T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 184. QATAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 185. QATAR T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 186. QATAR T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 187. RUSSIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 188. RUSSIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 192. SAUDI ARABIA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 197. SOUTH AFRICA T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 198. SOUTH AFRICA T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 202. SPAIN T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 203. SPAIN T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 204. SPAIN T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 205. SPAIN T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 206. SPAIN T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 208. SWEDEN T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 212. SWITZERLAND T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 213. SWITZERLAND T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 214. SWITZERLAND T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 215. SWITZERLAND T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 216. SWITZERLAND T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 217. TURKEY T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 218. TURKEY T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 219. TURKEY T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 220. TURKEY T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 221. TURKEY T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY MODALITY, 2018-2030 (USD MILLION)
TABLE 228. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 230. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM T-CELL THERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2030 (USD MILLION)
TABLE 232. T-CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 233. T-CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2023
TABLE 234. T-CELL THERAPY MARKET LICENSE & PRICING

Companies Mentioned

  • AbbVie Inc.
  • Adaptimmune Therapeutics PLC
  • Amgen Inc.
  • Bluebird Bio, Inc.
  • Bristol Myers Squibb
  • DiaCarta, Inc.
  • Fate Therapeutics Inc.
  • Gilead Sciences, Inc.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Poseida Therapeutics Inc.
  • Sorrento Therapeutics, Inc.
  • Takara Bio Inc.
  • Tessa Therapeutics Pte. Ltd.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages185
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 9.85 Billion
Forecasted Market Value ( USD ) by 2030 $ 31.3 Billion
Compound Annual Growth Rate21.2%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Global CAR T-cell Therapy Market by Indication (Hematologic Malignancies, Solid Tumors), End-Use (Cancer Treatment Centers, Hospitals) - Forecast 2024-2030 - Product Image

Global CAR T-cell Therapy Market by Indication (Hematologic Malignancies, Solid Tumors), End-Use (Cancer Treatment Centers, Hospitals) - Forecast 2024-2030

  • Report
  • 195 Pages
  • Global
From
T Cell Therapy Market Size and Forecasts 2020-2030, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Modality, Therapy Type [CAR T-cell Therapy and T-cell Receptor-based], Indication, and Geography - Product Image

T Cell Therapy Market Size and Forecasts 2020-2030, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Modality, Therapy Type [CAR T-cell Therapy and T-cell Receptor-based], Indication, and Geography

  • Report
  • 138 Pages
  • Global
From
Global T-Cell Therapy Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis - Product Image

Global T-Cell Therapy Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

  • Report
  • 191 Pages
  • Global
From
Global T-Cell Immunotherapy Market (2023-2028) Competitive Analysis, Impact of Economic Slowdown & Impending Recession, Ansoff Analysis - Product Image

Global T-Cell Immunotherapy Market (2023-2028) Competitive Analysis, Impact of Economic Slowdown & Impending Recession, Ansoff Analysis

  • Report
  • 183 Pages
  • Global
From
Global T-Cell Immunotherapy Market by Mechanism Of Action (Active Immunotherapy, Passive Immunotherapy), Product Class (Bispecific Antibodies, Cytokines, Monoclonal Antibodies), Type of Therapy, Indication - Forecast 2024-2030 - Product Image

Global T-Cell Immunotherapy Market by Mechanism Of Action (Active Immunotherapy, Passive Immunotherapy), Product Class (Bispecific Antibodies, Cytokines, Monoclonal Antibodies), Type of Therapy, Indication - Forecast 2024-2030

  • Report
  • 180 Pages
  • Global
From

About the T Cell Therapies Market

T Cell Therapies are a type of biotechnology that involves the use of a patient's own T cells to treat diseases. T cells are a type of white blood cell that play a key role in the body's immune system. T Cell Therapies involve the extraction of T cells from a patient, engineering them to recognize and attack specific targets, and then reintroducing them into the patient's body. This type of therapy has been used to treat a variety of cancers, including leukemia, lymphoma, and multiple myeloma. It has also been used to treat autoimmune diseases, such as rheumatoid arthritis and Crohn's disease. T Cell Therapies are a rapidly growing field of biotechnology, with many companies investing in research and development. Companies such as Kite Pharma, Juno Therapeutics, and Novartis are leading the way in developing and commercializing T Cell Therapies. Other companies, such as Gilead Sciences, Celgene, and Regeneron, are also investing in the field. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.